A. History of freezing: more than 4000 years ago, ancient Greece used ice to treat skin diseases; in 1845, Faraday M, used ice and salt water to freeze tumors; in 1945, Jarnott cryogenic treatment of tumors; in 1968, ultra-low temperature liquid nitrogen for prostate cancer and liver cancer; in 1990, liquid nitrogen in large quantities for prostate, liver and kidney diseases; in 1998, the U.S. argon helium knife treatment system was U.S. FDA approved for clinical use. In 1998, a new type of interventional therapy device —— with argon as the cold medium and helium as the hot medium was approved by FDA/EU and entered the medical market. Shandong Chest Hospital Oncology Center Zhang Feng Second, the principle of treatment: argon helium knife is based on a new refrigerant – argon, thermal medium – helium as a cryoconductive system, is the use of room temperature high pressure argon gas suddenly released into the low pressure area can produce ultra-low temperature principle. Argon gas rapid ultra-low temperature refrigeration technology, can be used to freeze the lesion tissue to -120 ℃ ~ -160 ℃ in ten seconds by the rapid release of argon gas in the tip of the knife. The helium gas can be released rapidly in the tip of the knife to thaw and rapidly re-temper the ice ball and raise the temperature. The speed, time and temperature of cooling and warming, the size and shape of the ice ball can be precisely set and controlled. Third, the treatment characteristics: cryo-targeted therapy compared with traditional freezing methods, a significant feature is the introduction of helium-targeted thermal effect system in the ultra-low temperature treatment system. Helium rapid warming technology, thermal effect technology, can be released rapidly by helium in the tip of the knife, the frozen lesion will begin to rapidly reheat and warm up in a few seconds, and quickly thaw the ice ball. The time, speed and temperature of warming can be set and controlled precisely. Clinical application: (1) Lung cancer: CT-guided percutaneous lung puncture targeted freeze-thaw therapy for lung cancer Indications: (1) single or multiple, primary or secondary intrapulmonary peripheral masses with a single tumor diameter greater than 1.0 cm; (2) unresectable central lung cancer; (3) metastatic lung cancer whose primary cancer has been better controlled or more limited; (4) cancer involving the mediastinum and pericardium in a large extent, but still without (5) those with malignant pleural fluid, but the primary foci are clearly shown; (2) liver cancer: CT-guided percutaneous lung puncture targeted freeze-thaw therapy for liver cancer Indications: (1) single or multiple, primary or secondary intrapulmonary peripheral masses with a single tumor diameter of 1-15 cm; (2) unresectable liver cancer with no more than four intrahepatic lesions and no extrahepatic metastatic lesions (3) Metastatic liver cancer whose primary cancer has been better controlled or more limited; (4) Huge cancer can be combined with hepatic artery chemoembolization and tumor reduction cryosurgery; (5) No intractable ascites; (6) Advantages of percutaneous percutaneous targeted freeze-thaw therapy (1) No incision, little trauma, no obvious pain, fast recovery after surgery; (2) Tumor cell death, pressure reduction, 1-3 months tumor shrinkage, clinical symptoms (3) The reactivation of the immune system of the body is conducive to the improvement of the quality of survival; (4) The efficacy is similar to surgical resection; (5) It is suitable for patients with all stages of tumor and for patients who are old and frail and whose other treatments have failed.